PBSV · XBRL financial data

Pharma-Bio Serv financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PBSV's year ends in late October)

In thousands of dollars	Q4 FY23Oct 31, 2023	Q1 FY24Jan 31, 2024	Q2 FY24Apr 30, 2024	Q3 FY24Jul 31, 2024	Q4 FY24Oct 31, 2024	Q1 FY25Jan 31, 2025	Q2 FY25Apr 30, 2025	Q3 FY25Jul 31, 2025	Q4 FY25Oct 31, 2025	Q1 FY26Jan 31, 2026	Q2 FY26Apr 30, 2026	Q3 FY26Jul 31, 2026
Revenue	3,598*	2,380	2,378	2,418	2,333*	2,471	2,417	1,963	2,150*	2,295	2,703	2,336
Cost of revenue	2,668*	1,845	1,759	1,783	1,607*	1,703	1,598	1,389	1,401*	1,573	1,801	1,644
Gross profit	930*	536	618	635	727*	768	819	574	749*	722	902	692
Selling, general and administrative	982*	974	932	1,017	881*	860	917	888	882*	817	757	764
Operating income (loss)	(52)*	(438)	(313)	(382)	(154)*	(92)	(98)	(314)	(133)*	(95)	145	(72)
Interest income	142*	182	26	73	(35)*	138	—	—	year only	83	—	—
Other income (expense)	4*	181	121	92	139*	102	199	105	138*	131	95	61
Income tax expense (benefit)	(1)*	13	21	19	(31)*	1	6	5	4*	4	6	3
Net income (loss)	(47)*	(271)	(214)	(309)	16*	9	95	(204)	(0)*	33	233	(14)
Earnings per share, diluted USD per share	0.00*	(0.01)	(0.01)	0.01	0.00*	0.00	0.00	0.01	0.00*	0.00	0.01	(0.00)
Weighted average shares, basic thousands of shares	23,010*	22,962	22,961	22,962	22,979*	22,958	22,934	22,927	22,969*	22,906	22,902	22,902
Weighted average shares, diluted thousands of shares	23,033*	22,986	22,969	22,962	22,980*	22,961	22,944	22,938	22,984*	22,913	22,912	22,911

Fiscal quarters (PBSV's year ends in late October)

In thousands of dollars	Q4 FY23Oct 31, 2023	Q1 FY24Jan 31, 2024	Q2 FY24Apr 30, 2024	Q3 FY24Jul 31, 2024	Q4 FY24Oct 31, 2024	Q1 FY25Jan 31, 2025	Q2 FY25Apr 30, 2025	Q3 FY25Jul 31, 2025	Q4 FY25Oct 31, 2025	Q1 FY26Jan 31, 2026	Q2 FY26Apr 30, 2026	Q3 FY26Jul 31, 2026
Cash and cash equivalents	10,446	6,414	3,509	6,520	6,767	7,307	2,093	3,958	3,379	5,764	1,791	1,518
Marketable securities	4,531	9,476	9,961	6,342	5,978	5,128	8,313	6,767	7,475	4,797	6,681	7,059
Accounts receivable	3,941	2,408	2,615	2,599	2,511	2,682	2,684	2,016	2,361	2,655	2,723	2,421
Prepaid and other current assets	—	—	—	—	442	—	327	415	172	109	91	240
Total current assets	19,401	18,775	16,513	15,936	15,699	15,535	13,417	13,156	13,387	13,324	11,286	11,239
Property and equipment, net	33	26	21	18	169	160	145	132	116	104	92	80
Right-of-use asset	356	318	279	239	199	157	115	73	29	0	0	0
Total assets	19,902	19,231	16,925	16,319	16,292	16,077	13,904	13,586	13,653	13,548	11,499	11,440
Total current liabilities	2,154	3,678	2,197	1,899	1,887	3,420	1,780	1,659	1,739	3,310	1,045	995
Lease liability, non-current	194	154	113	71	29	0	0	0	0	—	—	—
Total liabilities	3,775	5,075	2,971	2,632	2,577	4,081	1,780	1,659	1,739	3,310	1,045	995
Retained earnings	14,854	12,861	12,647	12,338	12,354	10,643	10,738	10,534	10,534	8,849	9,082	9,068
Total stockholders' equity	16,127	14,156	13,953	13,687	13,715	11,996	12,123	11,927	11,914	10,239	10,454	10,445
Total liabilities and equity	19,902	19,231	16,925	16,319	16,292	16,077	13,904	13,586	13,653	13,548	11,499	11,440
Common shares outstanding (cover page) thousands of shares	22,963	22,961	22,958	22,958	22,958	22,931	22,928	22,918	22,904	22,902	22,902	22,902

Fiscal quarters (PBSV's year ends in late October)

In thousands of dollars	Q4 FY23Oct 31, 2023	Q1 FY24Jan 31, 2024	Q2 FY24Apr 30, 2024	Q3 FY24Jul 31, 2024	Q4 FY24Oct 31, 2024	Q1 FY25Jan 31, 2025	Q2 FY25Apr 30, 2025	Q3 FY25Jul 31, 2025	Q4 FY25Oct 31, 2025	Q1 FY26Jan 31, 2026	Q2 FY26Apr 30, 2026	Q3 FY26Jul 31, 2026
Net income (loss)	(47)*	(271)	(214)	(309)	16*	9	95	(204)	(0)*	33	233	(14)
Stock-based compensation	1*	15	15	15	3*	11	10	10	4*	9	9	9
Net cash from operating activities	308*	726	(701)	(670)	78*	(429)	(302)	237	280*	(390)	(365)	61
Purchases of property and equipment	(2)*	1	0	2	157*	0	4	2	0*	2	2	1
Net cash from investing activities	7,327*	(4,763)	(459)	3,690	172*	988	(3,227)	1,629	(857)*	2,767	(1,887)	(326)
Share repurchases	1*	7	2	2	0*	0	17	5	9*	2	1	0
Dividends paid	0*	1,722	1,722	0	0*	—	1,720	0	0*	—	1,718	0
Net cash from financing activities	(1)*	(7)	(1,725)	(2)	0*	0	(1,737)	(5)	(9)*	(2)	(1,718)	0
Net change in cash	7,576*	(4,033)	(2,904)	3,011	247*	540	(5,214)	1,865	(579)*	2,384	(3,972)	(273)

SIC 8742 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8742 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Pharma-Bio Serv	1,518	2,336	61	22.9M	—	Q3 FY26 10-QJul 31, 2026
Panamera Holdings	0	0	(45)*	79.9M	0.0 quarters	Q3 FY26 10-QApr 30, 2026
Nordicus Partners	5.8	not reported	(160)	19.4M	0.0 quarters	Q1 FY27 10-QJun 30, 2026
RTB Digital	492	2,328	(3,104)*	14.0M	0.2 quarters	Q2 FY26 10-Q/AJun 30, 2026
Elvictor Group	285	707	202*	834,042	—	Q2 FY26 10-QJun 30, 2026
Aeries Technology	6,069	21,918	4,824	not reported	—	Q1 FY27 10-QJun 30, 2026
Greenpro Capital	634	302	(338)*	18.1M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Mastech Digital	37,939	41,987	2,648*	12.0M	—	Q3 FY26 10-QSep 30, 2026
CISO Global	722	5,791	(69)*	45.5M	10.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.